Recent Investment Analysts’ Ratings Changes for Gilead Sciences (GILD)

Gilead Sciences (NASDAQ: GILD) recently received a number of ratings updates from brokerages and research firms:

  • 11/18/2026 – Gilead Sciences was given a new $175.00 price target by TD Cowen.
  • 11/16/2026 – Gilead Sciences had its price target raised by Barclays from $145.00 to $160.00. They now have an “equal weight” rating on the stock.
  • 11/12/2026 – Gilead Sciences was given a new $190.00 price target by Argus.
  • 11/4/2026 – Gilead Sciences was given a new $196.00 price target by Jefferies Financial Group.
  • 11/2/2026 – Gilead Sciences had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $175.00 price target on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by UBS Group from $175.00 to $195.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Gilead Sciences was given a new $175.00 price target by Needham & Company LLC.
  • 10/30/2026 – Gilead Sciences had its price target raised by TD Cowen from $160.00 to $175.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $184.00 price target on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by JPMorgan Chase & Co. from $170.00 to $190.00. They now have an “overweight” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by Citigroup from $165.00 to $188.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by Scotiabank from $177.00 to $200.00. They now have a “sector outperform” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by Morgan Stanley from $163.00 to $183.00. They now have an “overweight” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by Truist Financial from $158.00 to $181.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by Wells Fargo & Company from $165.00 to $190.00. They now have an “overweight” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by Royal Bank Of Canada from $126.00 to $131.00. They now have a “sector perform” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by Needham & Company LLC from $170.00 to $200.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Gilead Sciences had its price target raised by Cantor Fitzgerald from $155.00 to $175.00. They now have an “overweight” rating on the stock.
  • 10/23/2026 – Gilead Sciences had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $185.00 price target on the stock.
  • 10/20/2026 – Gilead Sciences had its price target raised by Bank of America from $168.00 to $172.00. They now have a “buy” rating on the stock.
  • 10/12/2026 – Gilead Sciences had its “buy” rating reaffirmed by Bank of America. They now have a $164.00 price target on the stock.
  • 10/8/2026 – Gilead Sciences had its price target raised by Royal Bank Of Canada from $123.00 to $126.00. They now have a “sector perform” rating on the stock.
  • 10/8/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
  • 10/7/2026 – Gilead Sciences had its price target raised by Truist Financial from $150.00 to $158.00. They now have a “buy” rating on the stock.
  • 10/7/2026 – Gilead Sciences had its price target raised by JPMorgan Chase & Co. from $160.00 to $170.00. They now have an “overweight” rating on the stock.
  • 10/7/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $165.00 to $163.00. They now have an “overweight” rating on the stock.
  • 9/29/2026 – Gilead Sciences was downgraded by Zacks Research from “strong-buy” to “hold”.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $166.53 on Friday. The stock has a market cap of $206.55 billion, a PE ratio of -52.70 and a beta of 0.35. The stock has a 50-day moving average of $156.80 and a 200-day moving average of $142.34. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. Gilead Sciences’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.47 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.97 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -103.80%.

Insider Activity

In other news, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares of the company’s stock, valued at $1,916,306.28. The trade was a 58.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Keeley Cain Wettan sold 3,399 shares of the company’s stock in a transaction on Friday, November 6th. The shares were sold at an average price of $164.11, for a total transaction of $557,809.89. Following the completion of the sale, the executive vice president owned 5,360 shares of the company’s stock, valued at approximately $879,629.60. This represents a 38.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 237,709 shares of company stock valued at $39,799,137. 0.30% of the stock is owned by company insiders.

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Read More

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.